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Introduction: The main objective of individualization of treatment in IVF is to offer every sin-
gle  woman the best treatment tailored to her own unique characteristics, thus maximizing
the chances of pregnancy and eliminating the iatrogenic and avoidable risks resulting from
ovarian stimulation. Personalization of treatment in IVF should be based on the prediction
of  ovarian response.
Objective: To summarize the predictive ability of ovarian reserve markers, and the therapeu-
tic  strategies that have been proposed in IVF after this prediction.
Methods: A systematic review of the existing literature was performed by searching Medline,
LILACS, SciELO and Pubmed, for publications related to ovarian reserve markers and their
incorporation into controlled ovarian stimulation (COS) protocols in IVF.
Results: 251 articles were found. Ten articles published between 2010 and 2015 were selected.
Conclusion: Antral follicle count (AFC) and anti-Mullerian hormone (AMH), the most sensi-
tive markers of ovarian reserve, are ideal in planning personalized COS protocols. These
markers permit prediction of the ovarian response with reliable accuracy. Following the cat-
egorization of expected ovarian response clinicians can adopt tailored therapeutic strategies
for  each patient.
© 2016 Sociedade Brasileira de Reproduc¸a˜o Humana. Published by Elsevier Editora Ltda.
This  is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
Individualizac¸ão  da  estimulac¸ão  ovariana  controlada  na  fertilizac¸ão
in  vitro  com  o  uso  de  marcadores  da  reserva  ovariana:  uma  revisão
sistemática
r  e  s  u  m  oPalavras-chave:
FIV
Individualizac¸ão
Introduc¸ão: O principal objetivo da individualizac¸ão do tratamento na fertilizac¸ão in vitro é
oferecer a cada mulher o melhor tratamento sob medida para suas próprias características
∗ Corresponding author.
E-mail: drimedpuc@gmail.com (G.B. Guimarães).
http://dx.doi.org/10.1016/j.recli.2016.06.004
1413-2087/© 2016 Sociedade Brasileira de Reproduc¸a˜o Humana. Published by Elsevier Editora Ltda. This is an open access article under
the  CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
r e p r o d c l i m . 2 0 1 6;3  1(3):128–133 129
Reserva ovariana
Contagem de folículos antrais
Hormônio anti-Mülleriano
únicas, maximizar, assim, as chances de gravidez e eliminar os riscos de iatrogenia durante a
estimulac¸ão ovariana. A personalizac¸ão do tratamento na fertilizac¸ão in vitro deve basear-se
na  predic¸ão da resposta ovariana.
Objetivo: Avaliar o uso de marcadores da reserva ovariana para individualizac¸ão da dose
inicial do FSH nos ciclos de FIV.
Métodos: Revisão sistemática da literatura feita por meio de pesquisa Medline, Lilacs,
SciELO e PubMed, para publicac¸ões relacionadas com marcadores reserva ovariana e sua
incorporac¸ão, estimulac¸ão ovariana (COS) e protocolos controlados em fertilizac¸ão in vitro.
Resultados: Foram achados 251 artigos. Foram selecionados dez artigos publicados entre
2010 e 2015.
Conclusão: Contagem de folículos antrais (AFC) e hormônio anti-Müulleriano (AMH), os
marcadores mais sensíveis da reserva ovariana, são ideais no planejamento de protocolos
individualizados. Esses marcadores permitem previsão da resposta ovariana com conﬁanc¸a.
De  acordo com a resposta ovariana esperada, os clínicos podem adotar estratégias terapêu-
ticas  sob medida para cada paciente.
© 2016 Sociedade Brasileira de Reproduc¸a˜o Humana. Publicado por Elsevier Editora
Ltda. Este e´ um artigo Open Access sob uma licenc¸a CC BY-NC-ND (http://
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t is well established that successful IVF and embryo transfer
equires both stimulation of the ovary and suppression of the
ituitary. Thus, exogenous gonadotropins and gonadotrophin-
eleasing hormone (GnRH) analogues are considered the
ormones required to maximize IVF success.1
The daily dose of gonadotrophin administered in assisted
eproduction technology may be ﬁxed but usually it is progres-
ively increased or tapered according to the given patient’s
esponse.2
A key issue in the management of cycles is deﬁning the
ptimal starting dose of FSH for each patient in order to obtain
he optimization of response and outcomes whilst minimizing
he risks.3–5
In this article we  discuss the use of the most recently identi-
ed markers of ovarian reserve, to categorize women  based on
heir anticipated ovarian response. The marker-based strategy
f assessing ovarian reserve in women in order to select the
deal therapeutic approach in IVF is reviewed.
ethods
 systematic review was conducted of studies published from
anuary 2010 to December 2015 in English, Portuguese and
panish. The following databases were consulted: Medical
iterature Analysis and Retrieval System Online (MEDLINE),
iterature Latin American and Caribbean (LILACS), Scientiﬁc
lectronic Library Online (SciELO), and US National Library of
edicine (PubMed).
The descriptors used were: anti-Mullerian hormone (AMH),
ntral follicles, antral follicle count (AFC), ovarian reserve and
everal synonyms of IVF and ICSI. Among the studies identi-
ed, prospective studies, systematic reviews and retrospective
tudies that addressed ovarian reserve markers as predictors
f ovarian response and individualized optimal dose of follicle
timulating hormone (FSH) to reduce inappropriate responsescreativecommons.org/licenses/by-nc-nd/4.0/).
in an IVF cycle were selected. Inclusion criteria were studies
with a sample composed of women <40 years of age with reg-
ular menstrual cycles, without ovarian anatomical changes
and with causes of infertility treated by assisted reproduction
techniques (ART).
The studies were selected independently and blindly by
two authors according to the inclusion and exclusion crite-
ria. Where there was disagreement between the two  authors,
the opinion of a third author was employed.
Two hundred and ﬁfty-one published articles were iden-
tiﬁed from the descriptors and ﬁlters used. One hundred
and one articles were excluded by the title, by reading the
abstracts, or because of repetition in the databases, and 150
articles were selected that related ovarian reserve markers as
predictors of ovarian response to individualized optimal dose
of FSH to reduce inappropriate responses.
From these 150 articles, six that respected the inclusion
criteria deﬁned for this study were selected. The reference
lists of the selected articles were analyzed to investigate the
existence of new articles addressing the topic that could be
incorporated.
Four more  articles ﬁtting the proposed inclusion criteria
were included, making a total of 10 articles analyzed in this
study.
Fig. 1 shows the ﬂow chart summarizing the strategy
adopted to identify and include the studies. Because this study
used only data published in the literature, approval by an insti-
tutional review board was not required.
Results
Using the data from the articles, Table 1 was constructed for
comparative analysis. Six of the ten articles analyzed were
prospective studies dealing with clinical trials and cohort
studies, and two was case–control studies with retrospective
design. Furthermore, two systematic reviews were included in
this study.
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Inclusion criteria
-Use markers of ovarian reserve 
as parameters for choosing the 
gonadotropin dose
- Evaluation of patients of
childbearing age
Inclusion criteria
- Ovarian surgery absence 
and/or previous uterine
- Absence of endocrine 
comorbidities-metabolic
Eletronic data bases
MEDLINE, LILACS e SciELO
Identification of articles 251 and
Reading titles
Selection of 150 articles and 
reading the abstracts
Inclusion of 6 articles selected, 
evaluated and analyzed in full
Descriptors
Count antral follicles
Ovarian Reserve
Hormone Anti-Mullerian
Follicle Stimulating Hormone
Filter:
English language, Portuguese and 
Spanish
Period 2010-2015
Review the list of references
Inclusion of 4 studies
Total of 10 studies included
logyFig. 1 – Flowchart of the methodo
The earliest study was published in 2010 by Japrayakasan
et al., in England, while the most recent were published in
2015 by Castro et al., and Naether et al., in Brasil and Germany,
respectively. This study conducted in Germany, has the largest
sample, with 2579 patients.
The smaller study, with 131 women, was conducted in the
UK by Jayaprakasan et al., in 2010.
Discussion
The main goal of individualized treatment in IVF cycles is
to provide every patient with therapy based on their unique
characteristics, thereby permitting a greater chance of success
with lower risks from ovarian stimulation.6–8
A key factor determining the outcome of COS and subse-
quent IVF outcome is selection of the gonadotrophin starting
dose. The need for individualizing gonadotrophin dosage
derives from the assumption that variability in the functional
ovarian reserve (the pool of recruitable follicles) is very wide
and consequently a standard ﬁxed dose of gonadotrophin may
not be suitable for all women. employed in systematic review.
Correct individualization of the gonadotrophin start dose
is an extremely important clinical decision.9,10
The correct individualization of treatment protocols in IVF
should be based on the correct prediction of ovarian response
especially the extremes, namely poor and hyper response. The
aim is then to choose the ideal treatment protocol according to
this prediction. The prediction of a poor or hyper response also
allows clinicians to give women more  accurate information
regarding the likelihood of these scenarios occurring during
their IVF cycle.11
Patients may receive more  accurate information on possi-
ble protracted treatment, cycle cancellation OHSS, treatment
burden and reduced success. Finally, if personalization is
based on the accurate prediction of ovarian response, then the
prediction of ovarian response should be based on the most
sensitive markers of ovarian reserve.12,13
Lan et al. compared the efﬁcacy and safety of two  sim-
ple dosing algorithms, one based on AMH  and the other on
the AFC, to determine the starting dose rFSH for ovarian
stimulation in 348 women. This pilot study, concluded that,
with subtle differences, both AMH and AFC appear to have
the ability to predict poor ovarian response and guide the
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Table 1 – Summary of data found in the systematic review.
Author Year Place Type of study n Dose of FSH (UI) Mean of
retrieved
oocytes
Pregnancy rate (%) Severe OHSS Insufﬁcient
response
Predictive
variables of
ovarian
response
Japrayakasan et al. 2010 England Clinical trial 131 300/225 8.20/9.00 31/41 Zero (0%)/1.00 (1.5%) Zero (0%)/4
(6.1%)
AFC
Yates et al. 2011 England Case control 769 200 12.4/10.6 17.9/27.7 10 (2.9%)/5 (1.2%) 14 (4%)/14
(3.3%)
FSH, AMH
Oliveira et al. 2012 Brazil Clinical trial 101 150 9.7 32.7 Not informed Not informed Age, AMH, AFC
La Marca et al. 2012 Italy Cohort 346 225/nomogram 9.4 Not informed Not informed 10 (2.9%) Age, AMH, FSH
Van Tilborg et al. 2012 Netherlands Clinical trial 1500 150/100–450 Not informed Not informed Not informed Not informed AFC
La Marca et al. 2013 Italy Case control 505 Nomogram 9.20 Not informed Zero (0%) 16 (3.2%) Age, AFC, FSH
VTN Lan et al. 2013 Vietnam Clinical trial 348 150–375 10.8/13.6 38/46.9 Not informed 17 (9.8%)/8
(4.7%)
AMH, AFC
Naether et al. 2015 Germany Cohort 2579 35–450 10.6/11.4 38.8/34.8 5 (0.74%)/15 (0.83%) Not informed Age, AMH, FSH
AFC, antral follicle count; AMH, anti-Mullerian hormone; FSH, follicle stimulating hormone.
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starting dose of rFSH. Therefore, other factors might inﬂuence
the choice of test.14
Advantages of AMH  include intracycle stability and the fact
that concentrations can be determined from blood obtained
during routine IVF testing. In contrast, AFC needs to be
determined early in the follicular phase of the cycle by a
skilled ultrasound operator and the measurement requires
standardization.14
Although AFC is probably one of the most widely used
markers of ovarian reserve in the context of IVF, it is surprising
that there is currently a lack in the literature of simple mod-
els based on AFC as a single variable dictating the treatment
strategy.15
A large RCT, developed by Van Tilborg et al., is ongoing in
the Netherlands aimed at comparing the gonadotrophin start-
ing dose for ovarian stimulation in IVF dictated by AFC versus
a standard gonadotrophin dose. In this study women are cate-
gorized into groups based on AFC and randomized to receiving
either an individualized or standard gonadotrophin dose.
The objectives of this study are the success rates in terms
of the live birth rate and the evaluation of cost-effectiveness of
the individualization of the gonadotrophin dose on the basis
of AFC.16
In 2010, Jayaprakasan et al. used AFC as a predictor of ovar-
ian response to compare ﬁxed doses of gonadotropins (225
and 300 IU) and did not observe a signiﬁcant difference in the
number of oocytes retrieved in women undergoing these doses
during an IVF cycle.17
Regarding the use and efﬁcacy of serum AMH levels in
tailored treatment, a recent retrospective study studies have
been published comparing the study group undergoing a ther-
apeutic protocol based on AMH  levels versus a control group
undergoing treatment based on pretreatment FSH levels con-
ﬁrmed that tailored treatment based on AMH reduced the
incidence of OHSS.
Moreover, the study showed a signiﬁcant increase in both
pregnancy (17.9 versus 27.7%) and live birth rates (15.9 ver-
sus 23.9%) in the study group compared with the control
group. This seems to conﬁrm that individualized therapy can
improve IVF outcomes.
Finally, and not least importantly, the study group also
showed an important reduction of costs probably due to a
reduced incidence of OHSS and drug consumption.18
An easy to use algorithm to calculate the gonadotrophin
dose based on AFC has recently been published.
This model, although interesting, requires validation in an
independent cohort as it is based on a retrospective analysis.
The multivariate regression analysis showed that indepen-
dent predictors of ovarian response expressed in terms of
retrieved oocytes were age, AFC and Day 3 serum FSH, with
AFC being the most signiﬁcant predictor. The nomogram cal-
culated the gonadotrophin dose based on the age of the
woman, Day 3 serum FSH level and AFC.19
A similar nomogram based on AMH  had previously been
developed by the same group. The choice of developing two
different nomograms  based on AMH  or AFC followed the
recognition that clinicians usually rely on measuring one
marker of ovarian response, either AFC or AMH.
The multivariate AMH  based model was developed on
346 women undergoing ovarian stimulation with the same;3 1(3):128–133
protocol (the long GnRH agonist standard protocol) and the
same dose of gonadotrophin. The variables analyzed as pos-
sible predictors of ovarian response to stimulation were Day 3
serum FSH, estradiol, AMH, BMI and smoking status.
A multivariate regression analysis showed that indepen-
dent predictors of ovarian response, expressed in terms of
retrieved oocytes, were age, AMH  and Day 3 serum FSH
with AMH being the most signiﬁcant predictor. According
to the model, for women of similar age, the number of
retrieved oocytes per unit of gonadotrophin was reduced with
decreasing levels of basal AMH  and increasing levels of Day 3
serum FSH.
The multivariate model was the basis of a nomogram for
the selection of the most appropriate gonadotrophin start-
ing dose.20 As with the AFC-based nomogram, the model
incorporating AMH needs to be validated in an external and
independent population before adoption into routine clinical
practice.19,20
Oliveira et al. recently presented a new ovarian response
prediction index (ORPI), based on AMH  levels, AFC and age, and
set-up a study to verify whether it could be a reliable predictor
of the ovarian stimulation response. A total of 101 patients
were enrolled in the intracytoplasmic sperm injection (ICSI)
programme were included.
The ORPI values were calculated by multiplying the
AMH  level by the number of antral follicles, and the
result was divided by the age (years) of the patient
(ORPI = AMH × AFC/patient age).
The regression analysis demonstrated signiﬁcant
(p < 0.0001) positive correlations between the ORPI and
the total number of oocytes collected. The ORPI exhibited an
excellent ability to predict a low ovarian response and a good
ability to predict an excessive response and the occurrence of
pregnancy in infertile women.
The ORPI might be used to improve cost beneﬁt ratio
of ovarian stimulation regiments by guiding the selection
of medication and by modulating the doses and regimens
according to the actual needs of the patients.21
Naether et al. reported a postmarketing surveillance sur-
vey conducted to investigate the utility of the CONsistency in
r-FSH Starting dOses for individualized tReatmenT (CONSORT)
calculator for individualizing recombinant human follicle
stimulating hormone (r-hFSH) starting doses for controlled
ovarian stimulation (COS) in routine clinical practice.
In this large observational study, the starting doses of r-
hFSH for COS recommended by physicians in routine clinical
practice were generally higher than the CONSORT-calculated
doses.
In addition, most patients received an actual starting dose
of r-hFSH that was higher than the CONSORT-calculated dose,
suggesting a lack of trust by the physician in the CONSORT-
calculated dose.
Further research to evaluate the full clinical impact of
dosing algorithms on safety and efﬁcacy during COS is
warranted.22Conclusion
The availability of new markers of ovarian reserve, the
improvement in methodology for their measurement and the
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uge amount of clinical data have supported the view that
ndividualization in IVF is the way forward. Ovarian response
n IVF is a complex puzzle for which we now know the most
mportant pieces.
The correct measurement of markers of ovarian reserve
llows a scientiﬁc estimate of the pool of follicles that poten-
ially respond to ovarian stimulation.
Published studies indicate an important role for both AFC
nd AMH  in the prediction of the extremes of ovarian response
nd for enabling the subsequent individualization of a thera-
eutic strategy.
This is the basis for the correct selection of women for use
f the different GnRH analogues and, for the ﬁne tuning of the
onadotrophin dose.
The ultimate goal would be the selection of an effective
rotocol for ovarian stimulation which has to be well bal-
nced between the risk of maximal and suboptimal ovarian
esponse. The beneﬁts of a personalized therapy may include
educed incidence of risks and dropout as well as a reduced
reatment burden.
Nevertheless, a clear deﬁnition for modality of a correct
pplication of the individualized therapy is still required to
ptimize efﬁcacy and daily clinical management.
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